Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
about
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerGonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysisResponse to degarelix after resistance to leuprolide in a patient with metastatic prostate cancerIn search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growthIntegrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomesA prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea.Androgen deprivation therapy: past, present and future.Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.Degarelix: a review of its use in patients with prostate cancer.A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment.A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.Triptorelin for the relief of lower urinary tract symptoms in men with advanced prostate cancer: results of a prospective, observational, grouped-analysis study.Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer.Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients.Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.What determines testosterone levels?Androgen deprivation therapy improves pneumoperitoneum time during laparoscopic radical prostatectomy in Japanese patients with enlarged prostates.Can androgen-deprivation therapy obviate the need of channel transurethral resection of the prostate in advanced prostate cancer with urinary retention? A prospective study.Therapeutic outcomes of the LHRH antagonists.Impact of Androgen Deprivation Therapy on Volume Reduction and Lower Urinary Tract Symptoms in Patients with Prostate Cancer.Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study.Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
P2860
Q26744431-6BBE650E-21EF-44CF-8520-88C49A1AC357Q26777150-6F275E99-E616-408F-AE31-BFE99C751E03Q27022516-4A34DA22-4111-42BB-951A-270CFCECBAA9Q28545022-A30C5D20-B5DD-48C8-9C80-86B5CF932F5DQ30373008-FB62C132-C231-4CE0-A34B-8D9D42C3460EQ33890406-019F1E75-33F2-4431-ABEA-55DE6FE9CE19Q35797395-CE3AEA8E-95CA-41AD-A985-ECE05E9FE3A8Q35870468-67D80509-536E-4C10-B112-E4CB0B1EA24DQ36070721-B5587400-297F-4713-A3E4-9C578ED18A7FQ37554004-C10C2955-02E1-4D6A-AD06-75C438A05C36Q38016530-A24AE1FF-5F86-41D6-9E1A-F2988D75D9BAQ38105608-D5071ACF-BCC3-468F-984E-936078AEEC16Q38193002-B1CB80A7-D07F-4437-869F-66DC3F3F63DDQ38206404-D4A0E45A-B4C6-4CB5-A9C1-E31B0DE671D1Q38356515-D37705C6-83FA-4C01-8011-BE84378E4DB2Q38485721-F515987C-B060-43ED-B917-1F600062AC9FQ38658856-9580CD98-3393-4F98-ABD0-2889082C65AAQ38798811-EC6F9527-7A13-4706-8B69-D833A3DA5380Q38844498-AC3CEA6D-2C03-4142-9F67-BF11464B18FEQ38892158-91010F27-584A-4DD0-91B6-12E565DB59F2Q39036192-53015A05-00C0-4284-93EC-8120E47BCDDEQ39157031-93CEE71E-A477-467E-8F58-3642979B5843Q39193963-7D6B182A-3D2A-4CEA-8C38-9542F77C1D46Q39247489-2C6DD614-2AE7-4BC3-9A30-3D874B606478Q40018470-96FC2A48-309E-49CC-84FB-DE1EDD5390D9Q42183708-7280DE09-E027-41BC-9066-19253B225798Q43857472-A39B978F-0041-4439-8B44-136B3AA543DDQ47136887-9DD183EF-E36C-4F40-93D7-DE09C8A29224Q47859553-440BEEA9-EC30-4C37-B84C-ED0966310239Q48724046-1D7371E5-3009-46E3-A884-436E521E4D47Q51733811-95F512E0-FDD2-4C9A-8F3C-78976622832BQ52615484-92C1663A-9B9D-4C90-8FDD-A4B04C9E5C29
P2860
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@ast
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@en
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@nl
type
label
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@ast
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@en
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@nl
prefLabel
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@ast
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@en
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@nl
P2093
P2860
P1433
P1476
Androgen deprivation therapy f ...... s goserelin plus bicalutamide.
@en
P2093
Enrico Colli
Haluk Ozen
Jan-Erik Damber
Karol Axcrona
László B Tankó
Peter Klarskov
Sirpa Aaltomaa
P2860
P304
P356
10.1111/J.1464-410X.2012.11107.X
P50
P577
2012-04-13T00:00:00Z